Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lasofoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 17/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 9/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lasofoxifene SCHEMBL5727524 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL30170471 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL117914 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL30170470 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL117915 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL3774592 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL29454456 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL9885582 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL26815 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL3771361 | 0.99 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | CAMERON KIMBERLY O | 2010-12-16 | — | — | US | disclosed |
| US-RE39558-E1 | 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1411049-A1 | Estrogen Agonists/Antagonists | PFIZER INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20020132816-A1 | Estrogen agonists/antagonists for preventing breast cancer | CAMERON KIMBERLY O (US) | 2002-09-19 | — | — | US | disclosed |
| EP-0802910-B1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1151998-A1 | Estrogen agonists/antagonists | PFIZER INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6204286-B1 | 8-(P-(PYRROLIDINYLALKOXY)PHENYL)TETRAHYDRONAPHTHOLS | PFIZER INC | 2001-03-20 | — | — | US | disclosed |
| US-6153622-A | Estrogen agonists/antagonists | PFIZER, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-1004306-A2 | Estrogen agonists/antagonists | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5552412-A | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis | PFIZER INC (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885MLNR 104/4885 |
| US-20020132816-A1 | Estrogen agonists/antagonists for preventing breast cancer | GPER1, ESR1, BRCA1 | ESR1 2/4885ESR2 4/4885MLNR 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.